Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules

International Journal of Pharmaceutics

Volumn 324, Issue 1, 2006, Pages 37-42

  Hillaireau, H ^a   Le Doan, T ^a   Besnard, M ^a   Chacun, H ^a   Janin, J ^b   Couvreur, P ^a  

^a UNIV PARIS SUD   (France)

^b LABORATOIRE D ENZYMOLOGIE ET BIOCHIMIE STRUCTURALES   (France)

Author keywords

Azidothymidine triphosphate; Cidofovir; Nanocpasules; Poly(alkylcyanoacrylate)

Indexed keywords

ANTIVIRUS AGENT; AZIDOTHYMIDINE TRIPHOSPHATE; CIDOFOVIR; NANOCAPSULE; NUCLEOTIDE DERIVATIVE; OLIGONUCLEOTIDE; POLY(ISOBUTYL 2 CYANOACRYLATE); POLYMER; PYRIMIDINE NUCLEOSIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; MOLECULAR WEIGHT; PRIORITY JOURNAL;

EID: 33750027900     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.07.006     Document Type: Article

References (18)

1. Balzarini J., Herdewijn P., and De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264 (1989) 6127-6133
2. De Clercq E. Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus). Verh. K. Acad. Geneesk. Belg. 58 (1996) 19-49
3. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res. 55 (2002) 1-13
4. Guise V., Drouin J.Y., Benoit J., Mahuteau J., Dumont P., and Couvreur P. Vidarabine-loaded nanoparticles: a physicochemical study. Pharm. Res. 7 (1990) 736-741
5. Kukhanova M., Krayevsky A., Prusoff W., and Cheng Y.C. Design of anti-HIV compounds: from nucleoside to nucleoside 5′-triphosphate analogs. Problems and perspectives. Curr. Pharm. Des. 6 (2000) 585-598
6. Lambert G., Bertrand J.R., Fattal E., Subra F., Pinto-Alphandary H., Malvy C., Auclair C., and Couvreur P. EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279 (2000) 401-406
7. Lambert G., Fattal E., Pinto-Alphandary H., Gulik A., and Couvreur P. Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17 (2000) 707-714
8. Larder B.A. Inhibitors of HIV reverse transcriptase as antiviral agents and drug resistance. In: Skalka A.M., and Goff S.P. (Eds). Reverse Transcriptase (1993), Cold Spring Harbor Laboratory Press, New York 205-222
9. Lobenberg R., Araujo L., Von Briesen H., Rodgers E., and Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Contr. Rel. 50 (1998) 21-30
10. Lobenberg R., and Kreuter J. Macrophage targeting of azidothymidine: a promising strategy for AIDS therapy. AIDS Res. Hum. Retroviruses 12 (1996) 1709-1715
11. Molema G., Jansen R.W., Visser J., and Meijer D.K. Simultaneous analysis of azidothymidine and its mono-, di- and triphosphate derivatives in biological fluids, tissue and cultured cells by a rapid high-performance liquid chromatographic method. J. Chromatogr. 579 (1992) 107-114
12. Pitaksuteepong T., Davies N.M., Tucker I.G., and Rades T. Factors influencing the entrapment of hydrophilic compounds in nanocapsules prepared by interfacial polymerisation of water-in-oil microemulsions. Eur. J. Pharm. Biopharm. 53 (2002) 335-342
13. Schafer V., Von Briesen H., Andreesen R., Steffan A.M., Royer C., Troster S., Kreuter J., and Rubsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9 (1992) 541-546
14. Simeonova M., Velichkova R., Ivanova G., Enchev V., and Abrahams I. Poly(butylcyanoacrylate) nanoparticles for topical delivery of 5-fluorouracil. Int. J. Pharm. 263 (2003) 133-140
15. Simeonova M., Velichkova R., Ivanova G., Enchev V., and Abrahams I. Study on the role of 5-fluorouracil in the polymerization of butylcyanoacrylate during the formation of nanoparticles. J. Drug Target 12 (2004) 49-56
16. Tornevik Y., Ullman B., Balzarini J., Wahren B., and Eriksson S. Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem. Pharmacol. 49 (1995) 829-837
17. Van Rompay A.R., Johansson M., and Karlsson A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol. Ther. 100 (2003) 119-139
18. Watnasirichaikul S., Rades T., Tucker I.G., and Davies N.M. In vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol. 54 (2002) 473-480